ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although CML cells were known to be resistant to the ABL inhibitor imatinib, the resistant CML cells became sensitive to imatinib when it was administered together with sirolimus that inhibits MTOR34.